126 related articles for article (PubMed ID: 38341177)
21. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
22. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional lipid-coated calcium phosphate nanoplatforms for complete inhibition of large triple negative breast cancer via targeted combined therapy.
Tang J; Li B; Howard CB; Mahler SM; Thurecht KJ; Wu Y; Huang L; Xu ZP
Biomaterials; 2019 Sep; 216():119232. PubMed ID: 31195300
[TBL] [Abstract][Full Text] [Related]
24. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.
Gao LY; Liu XY; Chen CJ; Wang JC; Feng Q; Yu MZ; Ma XF; Pei XW; Niu YJ; Qiu C; Pang WH; Zhang Q
Biomaterials; 2014 Feb; 35(6):2066-78. PubMed ID: 24315577
[TBL] [Abstract][Full Text] [Related]
25. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
26. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
27. Effect of Cationic Lipid Type in Folate-PEG-Modified Cationic Liposomes on Folate Receptor-Mediated siRNA Transfection in Tumor Cells.
Hattori Y; Shimizu S; Ozaki KI; Onishi H
Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30991703
[TBL] [Abstract][Full Text] [Related]
28. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
29. Cation-free siRNA-cored nanocapsules for tumor-targeted RNAi therapy.
Huang X; Li J; Li G; Ni B; Liang Z; Chen H; Xu C; Zhou J; Huang J; Deng S
Acta Biomater; 2023 Apr; 161():226-237. PubMed ID: 36898473
[TBL] [Abstract][Full Text] [Related]
30. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
31. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
32. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
33. Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.
Ploeg EM; Samplonius DF; Xiong X; Ke X; Hendriks MAJM; Britsch I; van Wijngaarden AP; Zhang H; Helfrich W
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37734877
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.
Lo JH; Kwon EJ; Zhang AQ; Singhal P; Bhatia SN
Bioconjug Chem; 2016 Oct; 27(10):2323-2331. PubMed ID: 27583545
[TBL] [Abstract][Full Text] [Related]
35. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M
Sci Transl Med; 2023 May; 15(696):eabm1262. PubMed ID: 37196067
[TBL] [Abstract][Full Text] [Related]
36. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.
Parker CL; McSweeney MD; Lucas AT; Jacobs TM; Wadsworth D; Zamboni WC; Lai SK
Nanomedicine; 2019 Oct; 21():102076. PubMed ID: 31394261
[TBL] [Abstract][Full Text] [Related]
37. Optimization of lipid assisted polymeric nanoparticles for siRNA delivery and cancer immunotherapy.
Lin S; Jing H; Du X; Yang X; Wang J
Biomater Sci; 2024 Apr; 12(8):2057-2066. PubMed ID: 38469870
[TBL] [Abstract][Full Text] [Related]
38. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
[TBL] [Abstract][Full Text] [Related]
39. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.
Jarantow SW; Bushey BS; Pardinas JR; Boakye K; Lacy ER; Sanders R; Sepulveda MA; Moores SL; Chiu ML
J Biol Chem; 2015 Oct; 290(41):24689-704. PubMed ID: 26260789
[TBL] [Abstract][Full Text] [Related]
40. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
